Squarepoint’s Tandem Diabetes Care TNDM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-11,700
Closed -$421K 5418
2024
Q4
$421K Buy
11,700
+600
+5% +$20.3K ﹤0.01% 3887
2024
Q3
$471K Sell
11,100
-200
-2% -$8.48K ﹤0.01% 3142
2024
Q2
$455K Buy
11,300
+200
+2% +$8.34K ﹤0.01% 3146
2024
Q1
$393K Buy
+11,100
New +$297K ﹤0.01% 3213
2022
Q3
Sell
-23,200
Closed -$1.37M 3442
2022
Q2
$1.37M Buy
+23,200
New +$1.9M 0.01% 1400

Other funds holding TNDM

Squarepoint's TNDM Position: Q3 2025 in Review

Squarepoint sold out of Tandem Diabetes Care (TNDM) in Q3 2025, closing a stake of 180,660 shares — an estimated $3.37M sold.

Squarepoint first reported a position in TNDM in Q2 2017 and held it in 27 quarters. The position peaked at $21.2M in Q2 2022. 255 funds tracked by Wall St. Rank hold TNDM as of Q3 2025.

  • Squarepoint reported no remaining Tandem Diabetes Care position as of Q3 2025 after selling out during the quarter.
  • Squarepoint sold 180,660 Tandem Diabetes Care shares in Q3 2025, an estimated $3.37M.
  • Squarepoint first reported a position in Tandem Diabetes Care in Q2 2017 and held it in 27 quarters.
  • Squarepoint's Tandem Diabetes Care position peaked at $21.2M in Q2 2022.
  • 255 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.